Vivani Medical

Vivani Medical is a clinical-stage biotechnology company with a mission to free patients from medication adherence challenges through its proprietary, miniaturized, long-term drug implant platform, NanoPortal™. The company has successfully demonstrated the feasibility of its technology in a first-in-human Phase 1 trial (LIBERATE-1) and is now advancing a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. Its strategy leverages the validated efficacy of GLP-1 drugs while aiming to differentiate through superior convenience (semi-annual or annual dosing) and potentially improved tolerability via steady-state delivery.

The NanoPortal™ implant technology is a miniature, subdermal drug delivery system engineered to provide steady-state release of therapeutic agents over extended periods of six months to one year from a single, removable implant.